201 related articles for article (PubMed ID: 16184462)
21. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
Kaufmann M; Rody A
Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
[TBL] [Abstract][Full Text] [Related]
22. Bone mineral density and adjuvant therapy in breast cancer survivors.
Crandall C; Petersen L; Ganz PA; Greendale GA
Breast Cancer Res Treat; 2004 Dec; 88(3):257-61. PubMed ID: 15609128
[TBL] [Abstract][Full Text] [Related]
23. Exercise effects on bone mineral density in women with breast cancer receiving adjuvant chemotherapy.
Schwartz AL; Winters-Stone K; Gallucci B
Oncol Nurs Forum; 2007 May; 34(3):627-33. PubMed ID: 17573321
[TBL] [Abstract][Full Text] [Related]
24. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
Lee SA; Hwang SH; Ahn SG; Lee HM; Jeong J; Lee HD
Breast Cancer Res Treat; 2011 Dec; 130(3):863-70. PubMed ID: 21861101
[TBL] [Abstract][Full Text] [Related]
25. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.
Brufsky A; Harker WG; Beck JT; Carroll R; Tan-Chiu E; Seidler C; Hohneker J; Lacerna L; Petrone S; Perez EA
J Clin Oncol; 2007 Mar; 25(7):829-36. PubMed ID: 17159193
[TBL] [Abstract][Full Text] [Related]
26. Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study.
Debess J; Riis JØ; Engebjerg MC; Ewertz M
Breast Cancer Res Treat; 2010 May; 121(1):91-100. PubMed ID: 20306129
[TBL] [Abstract][Full Text] [Related]
27. Combination of radiological and biochemical methods to assess bone mineral density of mandible in fully edentulous patients after chemotherapy: a 5-year prospective study.
Loo WT; Jin LJ; Cheung MN; Chow LW; Wang M
Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S109-15. PubMed ID: 20374022
[TBL] [Abstract][Full Text] [Related]
28. Premature ovarian failure and body composition changes with adjuvant chemotherapy for breast cancer.
Gordon AM; Hurwitz S; Shapiro CL; LeBoff MS
Menopause; 2011 Nov; 18(11):1244-8. PubMed ID: 21814159
[TBL] [Abstract][Full Text] [Related]
29. Effects of vibration therapy on bone mineral density in postmenopausal women with osteoporosis.
Ruan XY; Jin FY; Liu YL; Peng ZL; Sun YG
Chin Med J (Engl); 2008 Jul; 121(13):1155-8. PubMed ID: 18710630
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial.
Sverrisdottir A; Nystedt M; Johansson H; Fornander T
Breast Cancer Res Treat; 2009 Oct; 117(3):561-7. PubMed ID: 19153828
[TBL] [Abstract][Full Text] [Related]
31. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
32. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
Bundred NJ; Campbell ID; Davidson N; DeBoer RH; Eidtmann H; Monnier A; Neven P; von Minckwitz G; Miller JC; Schenk NL; Coleman RE
Cancer; 2008 Mar; 112(5):1001-10. PubMed ID: 18205185
[TBL] [Abstract][Full Text] [Related]
33. Bone mineral density and bone turnover in postmenopausal women treated for breast cancer.
Waltman NL; Ott CD; Twiss JJ; Gross GJ; Lindsey AM; Moore TE
Cancer Nurs; 2008; 31(3):182-90. PubMed ID: 18453874
[TBL] [Abstract][Full Text] [Related]
34. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
35. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
36. Use of raloxifene among women with a history of breast cancer.
Habel LA; Pressman A; Ettinger B; Sidney S; Suh-Burgmann B; Fehrenbacher L; Quesenberry CP
Breast Cancer Res Treat; 2006 Mar; 96(2):123-9. PubMed ID: 16319985
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
38. Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy.
Swenson KK; Nissen MJ; Anderson E; Shapiro A; Schousboe J; Leach J
J Support Oncol; 2009; 7(3):101-7. PubMed ID: 19507458
[TBL] [Abstract][Full Text] [Related]
39. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma.
Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Rea S
Cancer; 2006 Feb; 106(3):514-23. PubMed ID: 16388519
[TBL] [Abstract][Full Text] [Related]
40. Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer.
Rossi E; Morabito A; De Maio E; Di Rella F; Esposito G; Gravina A; Labonia V; Landi G; Nuzzo F; Pacilio C; Piccirillo MC; D'Aiuto G; D'Aiuto M; Rinaldo M; Botti G; Gallo C; Perrone F; de Matteis A
J Clin Oncol; 2008 Jan; 26(2):264-70. PubMed ID: 18086795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
